CYTOSORBENTS CORPORATION Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
CYTOSORBENTS CORPORATION (CTSO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 1.10% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-03-30
- CYTOSORBENTS CORPORATION effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was 1.10%, a 38.89% decline from fiscal 2023.
- CYTOSORBENTS CORPORATION effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was 1.80%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2024-12-31 | 1.10% 10-K · filed 2026-03-30 |
| 2023-12-31 | 1.80% 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |